Moleculin’s Annamycin Shows Strong Interim Results in Venetoclax-Failed AML Patients
Event summary
- Moleculin’s MIRACLE trial for Annamycin in relapsed/refractory AML reports a blinded composite remission rate (CRc) of 37% in venetoclax-failed patients, significantly higher than the published salvage remission rate of ~13%.
- Enrollment reaches 74 of 90 patients, with final Part A treatment expected in September 2026 and comprehensive unblinded results anticipated between December 2026 and February 2027.
- No evidence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines.
The big picture
Moleculin’s positive interim data for Annamycin in a challenging patient population—those who have failed venetoclax therapy—positions the drug as a potential differentiator in the relapsed/refractory AML space. The absence of cardiotoxicity further strengthens its profile against conventional anthracyclines, addressing a critical unmet need in oncology treatment.
What we're watching
- Efficacy Validation
- Whether the unblinded Part A results will confirm Annamycin’s superiority over the control arm, particularly in venetoclax-failed patients.
- Regulatory Pathway
- The pace at which Moleculin can advance into Part B of the MIRACLE trial and secure regulatory approval for Annamycin.
- Strategic Partnering
- How the upcoming milestones will impact Moleculin’s ability to attract strategic partners or investors.
Related topics